CY1124331T1 - Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης - Google Patents
Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονηςInfo
- Publication number
- CY1124331T1 CY1124331T1 CY20211100340T CY211100340T CY1124331T1 CY 1124331 T1 CY1124331 T1 CY 1124331T1 CY 20211100340 T CY20211100340 T CY 20211100340T CY 211100340 T CY211100340 T CY 211100340T CY 1124331 T1 CY1124331 T1 CY 1124331T1
- Authority
- CY
- Cyprus
- Prior art keywords
- active substance
- increased bioavailability
- naltrexone therapy
- naltrexone
- therapy
- Prior art date
Links
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title abstract 2
- 229960003086 naltrexone Drugs 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Αποκαλύπτονται συνθέσεις, χρήσεις, μέθοδοι και κιτ για την αύξηση της βιοδιαθεσιμότητας της δραστικής ουσίας σε μία θεραπεία ναλτρεξόνης.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41939510P | 2010-12-03 | 2010-12-03 | |
| PCT/US2011/063177 WO2012075459A1 (en) | 2010-12-03 | 2011-12-02 | Increasing drug bioavailability in naltrexone therapy |
| EP11845186.3A EP2646031B9 (en) | 2010-12-03 | 2011-12-02 | Increasing drug bioavailability in naltrexone therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124331T1 true CY1124331T1 (el) | 2022-07-22 |
Family
ID=46172304
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100524T CY1118968T1 (el) | 2010-12-03 | 2017-05-18 | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης |
| CY20211100340T CY1124331T1 (el) | 2010-12-03 | 2021-04-19 | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100524T CY1118968T1 (el) | 2010-12-03 | 2017-05-18 | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20130245056A1 (el) |
| EP (4) | EP4349369A3 (el) |
| JP (5) | JP6008866B2 (el) |
| KR (5) | KR102258043B1 (el) |
| CN (1) | CN103313711A (el) |
| AR (2) | AR093182A1 (el) |
| AU (2) | AU2011336304B2 (el) |
| BR (1) | BR112013013390A2 (el) |
| CA (2) | CA3239386A1 (el) |
| CL (1) | CL2013001564A1 (el) |
| CY (2) | CY1118968T1 (el) |
| DK (3) | DK3222280T3 (el) |
| ES (2) | ES2866879T3 (el) |
| FI (1) | FI3884947T3 (el) |
| HR (3) | HRP20240115T1 (el) |
| HU (3) | HUE065852T2 (el) |
| IL (3) | IL226504B (el) |
| LT (3) | LT3222280T (el) |
| MX (1) | MX356801B (el) |
| PL (3) | PL3222280T3 (el) |
| PT (3) | PT3884947T (el) |
| RS (3) | RS65198B1 (el) |
| RU (1) | RU2640561C2 (el) |
| SI (3) | SI3884947T1 (el) |
| SM (3) | SMT202100227T1 (el) |
| TW (1) | TWI618536B (el) |
| WO (1) | WO2012075459A1 (el) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
| WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| EP2303025A4 (en) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | METHOD FOR TREATING DIGITAL FAT SWITCHES |
| JP6196041B2 (ja) | 2010-01-11 | 2017-09-13 | オレキシジェン・セラピューティクス・インコーポレーテッド | 大うつ病を有する患者において減量療法を提供する方法 |
| TWI618536B (zh) * | 2010-12-03 | 2018-03-21 | 歐瑞根治療有限公司 | 於納曲酮療法中增加藥物生物可利用性 |
| RS60682B1 (sr) | 2012-06-06 | 2020-09-30 | Nalpropion Pharmaceuticals Llc | Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom |
| WO2016125109A1 (en) * | 2015-02-07 | 2016-08-11 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition for the treatment of obesity |
| US20200101066A1 (en) * | 2017-03-28 | 2020-04-02 | LDN Pharma Limited | Agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer |
| EP3482751A1 (en) * | 2017-11-14 | 2019-05-15 | LDN Pharma Limited | Cancer treatment |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10129265A1 (de) * | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| US6972291B2 (en) * | 2002-07-02 | 2005-12-06 | Bernstein Richard K | Method for reducing food intake |
| EP1772147A2 (en) * | 2003-03-17 | 2007-04-11 | Japan Tobacco, Inc. | Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| PT2316456T (pt) | 2003-04-29 | 2017-09-05 | Orexigen Therapeutics Inc | Composições para afetar a perda de peso compreendendo naltrexona e bupropion |
| KR20080042092A (ko) | 2005-07-27 | 2008-05-14 | 오렉시젠 세러퓨틱스 인크. | 체중감량 조성물 |
| US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| WO2007089318A2 (en) | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| TW200803901A (en) | 2005-11-28 | 2008-01-16 | Orexigen Therapeutics Inc | Methods of treating anxiety disorders |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| HUE032156T2 (en) * | 2006-06-19 | 2017-09-28 | Alpharma Pharmaceuticals Llc | Pharmaceutical preparations |
| KR101264789B1 (ko) | 2006-06-30 | 2013-05-15 | 엘지디스플레이 주식회사 | 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법 |
| WO2008011150A1 (en) * | 2006-07-20 | 2008-01-24 | Somaxon Pharmaceuticals, Inc. | Methods of improving the pharmacokinetics of doxepin |
| AU2007319472B2 (en) | 2006-11-09 | 2013-01-17 | Nalpropion Pharmaceuticals Llc | Methods Of Administering Weight Loss Medications |
| KR101971218B1 (ko) | 2006-11-09 | 2019-08-27 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
| CN101678025A (zh) * | 2007-04-11 | 2010-03-24 | 生物马林药物股份有限公司 | 四氢生物蝶呤组合物及其测量方法 |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| WO2009035473A2 (en) * | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
| EP2303025A4 (en) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | METHOD FOR TREATING DIGITAL FAT SWITCHES |
| TWI618536B (zh) * | 2010-12-03 | 2018-03-21 | 歐瑞根治療有限公司 | 於納曲酮療法中增加藥物生物可利用性 |
-
2011
- 2011-12-02 TW TW100144442A patent/TWI618536B/zh active
- 2011-12-02 CN CN2011800638854A patent/CN103313711A/zh active Pending
- 2011-12-02 EP EP23209711.3A patent/EP4349369A3/en active Pending
- 2011-12-02 KR KR1020207011510A patent/KR102258043B1/ko active Active
- 2011-12-02 ES ES17156985T patent/ES2866879T3/es active Active
- 2011-12-02 HR HRP20240115TT patent/HRP20240115T1/hr unknown
- 2011-12-02 SM SM20210227T patent/SMT202100227T1/it unknown
- 2011-12-02 ES ES11845186.3T patent/ES2625527T3/es active Active
- 2011-12-02 HU HUE21152314A patent/HUE065852T2/hu unknown
- 2011-12-02 KR KR1020217015625A patent/KR102391511B1/ko active Active
- 2011-12-02 SI SI201132102T patent/SI3884947T1/sl unknown
- 2011-12-02 KR KR1020137017317A patent/KR20140035320A/ko not_active Ceased
- 2011-12-02 HU HUE17156985A patent/HUE053831T2/hu unknown
- 2011-12-02 LT LTEP17156985.8T patent/LT3222280T/lt unknown
- 2011-12-02 AU AU2011336304A patent/AU2011336304B2/en active Active
- 2011-12-02 WO PCT/US2011/063177 patent/WO2012075459A1/en active Application Filing
- 2011-12-02 EP EP11845186.3A patent/EP2646031B9/en active Active
- 2011-12-02 DK DK17156985.8T patent/DK3222280T3/da active
- 2011-12-02 PL PL17156985T patent/PL3222280T3/pl unknown
- 2011-12-02 SM SM20170232T patent/SMT201700232T1/it unknown
- 2011-12-02 PT PT211523147T patent/PT3884947T/pt unknown
- 2011-12-02 RS RS20240196A patent/RS65198B1/sr unknown
- 2011-12-02 PL PL11845186T patent/PL2646031T3/pl unknown
- 2011-12-02 KR KR1020197014576A patent/KR102105857B1/ko active Active
- 2011-12-02 MX MX2013006071A patent/MX356801B/es active IP Right Grant
- 2011-12-02 BR BR112013013390A patent/BR112013013390A2/pt not_active Application Discontinuation
- 2011-12-02 RS RS20170491A patent/RS56014B1/sr unknown
- 2011-12-02 SI SI201131199A patent/SI2646031T1/sl unknown
- 2011-12-02 HU HUE11845186A patent/HUE034393T2/en unknown
- 2011-12-02 US US13/991,137 patent/US20130245056A1/en not_active Abandoned
- 2011-12-02 SM SM20240038T patent/SMT202400038T1/it unknown
- 2011-12-02 FI FIEP21152314.7T patent/FI3884947T3/fi active
- 2011-12-02 KR KR1020187016354A patent/KR101984500B1/ko active Active
- 2011-12-02 RS RS20210469A patent/RS62149B1/sr unknown
- 2011-12-02 PT PT171569858T patent/PT3222280T/pt unknown
- 2011-12-02 DK DK11845186.3T patent/DK2646031T3/en active
- 2011-12-02 EP EP21152314.7A patent/EP3884947B1/en active Active
- 2011-12-02 JP JP2013542229A patent/JP6008866B2/ja active Active
- 2011-12-02 PT PT118451863T patent/PT2646031T/pt unknown
- 2011-12-02 LT LTEP21152314.7T patent/LT3884947T/lt unknown
- 2011-12-02 LT LTEP11845186.3T patent/LT2646031T/lt unknown
- 2011-12-02 CA CA3239386A patent/CA3239386A1/en active Pending
- 2011-12-02 PL PL21152314.7T patent/PL3884947T3/pl unknown
- 2011-12-02 EP EP17156985.8A patent/EP3222280B1/en active Active
- 2011-12-02 DK DK21152314.7T patent/DK3884947T3/da active
- 2011-12-02 CA CA2819262A patent/CA2819262C/en active Active
- 2011-12-02 SI SI201131967T patent/SI3222280T1/sl unknown
- 2011-12-02 AR ARP110104512A patent/AR093182A1/es not_active Application Discontinuation
- 2011-12-02 RU RU2013127423A patent/RU2640561C2/ru active
-
2013
- 2013-05-23 IL IL226504A patent/IL226504B/en active IP Right Grant
- 2013-05-31 CL CL2013001564A patent/CL2013001564A1/es unknown
-
2016
- 2016-09-12 JP JP2016177391A patent/JP6456890B2/ja active Active
-
2017
- 2017-05-16 HR HRP20170734TT patent/HRP20170734T1/hr unknown
- 2017-05-18 CY CY20171100524T patent/CY1118968T1/el unknown
- 2017-06-26 AU AU2017204309A patent/AU2017204309A1/en not_active Abandoned
-
2018
- 2018-12-19 JP JP2018237245A patent/JP7025319B2/ja active Active
-
2019
- 2019-11-21 IL IL270841A patent/IL270841A/en unknown
-
2020
- 2020-12-21 IL IL279626A patent/IL279626A/en unknown
-
2021
- 2021-04-19 CY CY20211100340T patent/CY1124331T1/el unknown
- 2021-04-19 HR HRP20210618TT patent/HRP20210618T1/hr unknown
- 2021-12-23 AR ARP210103655A patent/AR124500A2/es unknown
-
2022
- 2022-02-10 JP JP2022019546A patent/JP2022060331A/ja active Pending
-
2024
- 2024-03-27 JP JP2024051334A patent/JP2024071605A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124331T1 (el) | Αυξημενη βιοδιαθεσιμοτητα δραστικης ουσιας σε θεραπεια ναλτρεξονης | |
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1122480T1 (el) | Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας | |
| CY1123208T1 (el) | Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων | |
| CY1120318T1 (el) | Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων | |
| CY1124144T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης | |
| CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
| TR201813877T4 (tr) | Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler. | |
| EA201171367A1 (ru) | Винилиндазолильные соединения | |
| CY1119518T1 (el) | Τροποποιημενα αντιγονα φυματιωσης | |
| PH12014501844B1 (en) | Peptidomimetic macrocycles | |
| MX2020010607A (es) | Compuestos y metodos para inhibir el transporte de fosfato. | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| EA201391351A1 (ru) | Способы повышения эффективности folr1 терапии рака | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| EA201270722A1 (ru) | Формы рифаксимина и их применение | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| NZ730763A (en) | Methods of treating a tauopathy | |
| CY1115254T1 (el) | Φαρμακευτικα διαλυματα, διαδικασιες για την παρασκευη τους και θεραπευτικες χρησεις | |
| EA201270619A1 (ru) | Применение бетанехола для лечения ксеростомии | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| EA201170227A1 (ru) | Имидазолкарбоксамиды | |
| AU2013225533A8 (en) | Amido spirocyclic amide and sulfonamide derivatives |